Drawing on the legacy of innovator and humanitarian Alfred E. Mann, we aim to develop therapeutic products and technologies that can help people manage serious medical conditions so that they can experience the very best that life has to offer.
With our ultra rapid-acting inhaled insulin, Afrezza®, we are changing the way diabetes is treated and, with our innovative Technosphere® technology, we are developing new ways for people with endocrine and orphan lung diseases to truly thrive.
We are driven to find new ways to change lives for the better. To keep working toward a world without limit for all.
To help more people live life more humann.SM
At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers we serve.
Alfred E. Mann was a visionary in aerospace, medical technology, and biopharmaceuticals, but his true passion was helping people. During his career, he founded 17 companies and developed breakthrough medical devices, including cardiac pacemakers, insulin pumps, cochlear implants, retinal prostheses, and other technologies that enabled people to live fuller, healthier lives.
In 1997, Al saw the potential of a dry powder insulin formulation to change the way diabetes is treated. He passed away in 2016, but we’re proud to have brought Afrezza® to market and continue his mission to help people not just manage their conditions, but really, truly live.
First international sale of Afrezza® (Brazil).
IND for TreT submitted to FDA; Phase 1 clinical study conducted; TreT licensed to United Therapeutics.
MannKind regains commercial rights to Afrezza®, begins sales and marketing efforts.
Formulation work commences on Treprostinil Technosphere (TreT).
Technosphere insulin (now Afrezza®) receives FDA approval.
Additional Phase 3 studies of Technosphere insulin conducted using next-generation inhaler (Dreamboat®).
NDA for Technosphere insulin is submitted to the FDA.
Commercial manufacturing facility in Danbury is expanded and renovated.
MannKind closes its initial public offering.
PDC merges with two other Mann-affiliated biopharmaceutical companies–CTL ImmunoTherapies Corp. and AlleCure Corp–the surviving company is named MannKind Corporation.
IND for Technosphere insulin submitted to the U.S. FDA; PDC relocates to Danbury, CT.
Glucose clamp clinical study of Technosphere insulin conducted in Germany.
Alfred E. Mann (then chairman of MiniMed Inc.) becomes involved with PDC.
PDC files the first patents for Technosphere® Technology.
Pharmaceutical Discovery Corporation (PDC) is incorporated; establishes a R&D facility in Elmsford, NY.